Exact Mass: 506.2906

Exact Mass Matches: 506.2906

Found 500 metabolites which its exact mass value is equals to given mass value 506.2906, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Mucronine A

C29H38N4O4 (506.2893)

4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside]

2-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[4-(1-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl)butan-2-yl]oxy}oxane-3,4,5-triol

C24H42O11 (506.2727)

4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is found in fruits. 4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is a constituent of Cydonia vulgaris (quince). Constituent of Cydonia vulgaris (quince). 4-Megastigmene-6a,9R-diol 9-[apiosyl-(1->6)-glucoside] is found in fruits.

(3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside]

2-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[4-(4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-yl]oxy}oxane-3,4,5-triol

C24H42O11 (506.2727)

(3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is found in tea. (3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is a constituent of leaves of Camellia sinensis var. sinensis (China tea). Constituent of leaves of Camellia sinensis variety sinensis (China tea). (3b,9R)-5-Megastigmene-3,9-diol 9-[apiosyl-(1->6)-glucoside] is found in tea.

(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide

6-(1-hydroxy-1-{7,8,11-trihydroxy-2,15-dimethyl-3-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydro-2H-pyran-2-one

C28H42O8 (506.288)

(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits. (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). (5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide is found in fruits.

Ixabepilone

(1S,3S,7R,10S,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

C27H42N2O5S (506.2814)

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone lactam modification that

Bemcentinib

1-{3,4-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl}-N3-[7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine

C30H34N8 (506.2906)

Abemaciclib

N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]pyrimidin-2-amine

C27H32F2N8 (506.2718)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

Chromogenic Substrate S-2266

2-[(2-Amino-1-hydroxy-3-methylbutylidene)amino]-N-{4-carbamimidamido-1-[(4-nitrophenyl)carbamoyl]butyl}-4-methylpentanimidate

C23H38N8O5 (506.2965)

Amoritin

vielanin A

C32H42O5 (506.3032)

isoamoritin

tussilagolactone

C28H42O8 (506.288)

Asn Val Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-methylbutanamido]-3-phenylpropanamido]hexanoic acid

C24H38N6O6 (506.2853)

Phe Val Ile Glu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-methylpentanamido]pentanedioic acid

C25H38N4O7 (506.274)

Asn Phe Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-phenylpropanamido]propanamido]-5-carbamimidamidopentanoic acid

C22H34N8O6 (506.2601)

C30H38N2O5_(1E)-6-Hydroxy-12-(1H-indol-3-ylmethyl)-7-methoxy-4,13,13a-trimethyl-5,6,7,8,12,12a,13,13a,14a,14b-decahydro-3H-cycloundeca[d]oxireno[f]isoindole-9,10(4H,11H)-dione

NCGC00347846-02_C30H38N2O5_(1E)-6-Hydroxy-12-(1H-indol-3-ylmethyl)-7-methoxy-4,13,13a-trimethyl-5,6,7,8,12,12a,13,13a,14a,14b-decahydro-3H-cycloundeca[d]oxireno[f]isoindole-9,10(4H,11H)-dione

C30H38N2O5 (506.2781)

C24H42O11_beta-D-Glucopyranoside, (1S,4R,5R)-4-[(1E,3R)-3-hydroxy-1-buten-1-yl]-3,3,5-trimethylcyclohexyl 6-O-[(2R,3R,4R)-tetrahydro-3,4-dihydroxy-4-(hydroxymethyl)-2-furanyl]

NCGC00386012-01_C24H42O11_beta-D-Glucopyranoside, (1S,4R,5R)-4-[(1E,3R)-3-hydroxy-1-buten-1-yl]-3,3,5-trimethylcyclohexyl 6-O-[(2R,3R,4R)-tetrahydro-3,4-dihydroxy-4-(hydroxymethyl)-2-furanyl]-

C24H42O11 (506.2727)

C28H42O8 (506.288)

(E)-12-((1H-indol-3-yl)methyl)-6-hydroxy-7-methoxy-4,13,13a-trimethyl-3,5,6,7,8,11,12,12a,13,13a,14a,14b-dodecahydro-9H-cycloundeca[d]oxireno[2,3-f]isoindole-9,10(4H)-dione

C30H38N2O5 (506.2781)

LPG 18:3

1-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C24H43O9P (506.2645)

ST 28:4;O3;S

(16S,20S,24E)-16,20- dihydroxy-19-norstigmasta-1,3,5(10),24(28)-tetraen-3-yl sulfate

C28H42O6S (506.2702)

Zenkersterone

2beta,3beta,14alpha 20R-tetrahydroxy-26(22)-olid-5beta-ergost-7-en-6-one

C28H42O8 (506.288)

(22E)-26,26,26,27,27,27-hexafluoro-25-hydroxy-22,23-didehydrovitamin D3

(5Z,7E,22E)-(3S)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19),22-cholestatetraene-3,25-diol

C27H36O2F6 (506.2619)

2,3-Bis[(1-oxooctyl)oxy]propyl beta-D-galactopyranoside

C25H46O10 (506.3091)

Bemcentinib

C30H34N8 (506.2906)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

R428 R-Enantiomer

C30H34N8 (506.2906)

Philanthotoxin 74

C24H44Cl2N4O3 (506.279)

Abemaciclib

C27H32F2N8 (506.2718)

1,2-Dioctanoyl-3-beta-d-galactosyl-sn-glycerol

C25H46O10 (506.3091)

A 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as octanoyl.

Ile-Leu-Val-Tyr

(2r,3r,4s,5s,6r)-2-{[(1s)-4-[(3r)-3-hydroxybutyl]-3,5,5-trimethylcyclohex-3-en-1-yl]oxy}-6-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C24H42O11 (506.2727)

(20r,22r)-5α,6β,14α,20,27-pentahydroxy-1-oxowitha-24-enolide

C28H42O8 (506.288)

{"Ingredient_id": "HBIN003440","Ingredient_name": "(20r,22r)-5\u03b1,6\u03b2,14\u03b1,20,27-pentahydroxy-1-oxowitha-24-enolide","Alias": "NA","Ingredient_formula": "C28H42O8","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C(C)(C2CCC3(C2(CCC4C3CC(C5(C4(C(=O)CCC5)C)O)O)C)O)O)CO","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16845","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(3r,9s)-megastigman-5-en-3,9-diol-3-o-[α-l-arabinofuranosyl-(1→6)]-β-d-glucopyranoside

(6r)-6-[(1s)-1-[(1r,3as,3bs,5r,5ar,6s,7s,9ar,9bs,11as)-5,5a,6,7-tetrahydroxy-9a,11a-dimethyl-9-oxo-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

(6r)-6-[(1s)-1-[(1r,3as,3bs,5r,5ar,6s,7s,9ar,9bs,11as)-5,5a,6,7-tetrahydroxy-9a,11a-dimethyl-9-oxo-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

(3s,4s)-4-[(2r,3r)-3-[(1s,3as,5ar,7s,8s,9ar,9br,11ar)-3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,3-dihydroxybutyl]-3-methyloxolan-2-one

(1s,3ar,3bs,7s,9ar,9bs,10s,11s,11as)-1-acetyl-10-(acetyloxy)-3a,3b,7-trihydroxy-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl 3-methylbutanoate

C28H42O8 (506.288)

(2e)-2-[(6e)-3,13-dihydroxy-8,12,14-trimethyl-16-phenylhexadeca-4,6,8,10-tetraen-1-ylidene]-5-hydroxy-4,6-dimethyl-6h-pyran-3-one

C32H42O5 (506.3032)

(3s,4s)-4-[(2r,3r)-3-[(1s,3as,5ar,7r,8s,9ar,9br,11ar)-3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,3-dihydroxybutyl]-3-methyloxolan-2-one

(2e,5e,9z,13e)-15-(acetyloxy)-2-[2-(acetyloxy)ethylidene]-10-[(acetyloxy)methyl]-6,14-dimethylpentadeca-5,9,13-trien-1-yl acetate

C28H42O8 (506.288)

(3r,4s,6r)-6-[(1s)-1-[(1s,3ar,3br,5r,5ar,9ar,9bs,11as)-1,3a,5,5a-tetrahydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3bh,4h,5h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyloxan-2-one

(3r,4s,6r)-6-[(1s)-1-[(1s,3ar,3br,5r,5ar,9ar,9bs,11as)-1,3a,5,5a-tetrahydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3bh,4h,5h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyloxan-2-one

C28H42O8 (506.288)

(4s)-4-[8-(3-ethoxy-3-methylbutyl)-2,2-dimethyl-3,4-dihydro-1-benzopyran-6-yl]-12,12-dimethyl-3,11-dioxatricyclo[8.4.0.0²,⁷]tetradeca-1,7,9-trien-6-one

C32H42O5 (506.3032)

(2r,3r,4s,5s,6r)-2-{[(1s,4r,5r)-4-[(1e,3r)-3-hydroxybut-1-en-1-yl]-3,3,5-trimethylcyclohexyl]oxy}-6-({[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C24H42O11 (506.2727)